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Loss of function mutations in the a3 or a4 chain of type IV
collagen cause Alport nephropathy, characterized by
progressive glomerulosclerosis. While studying the
mechanisms that determine disease progression, we found
that the evolution of kidney disease in Col4a3-deficient mice
was associated with an influx of immune cell subsets
including nonactivated macrophages. This suggested that
intrarenal inflammation might accelerate Alport
nephropathy. A possible mechanism might be the well-
known enhancement of immune recognition by bacterial
products. We found that exposure to bacterial endotoxin
from 4 to 6 weeks of age did not affect disease progression,
whereas an equipotent dose of cytosine–guanine (CpG)-DNA,
a synthetic mimic of bacterial DNA, accelerated all aspects of
Alport nephropathy and reduced the overall lifespan of
Col4a3-deficient mice. This effect was associated with a
significant increase of renal CD11bþ /Ly6Chi macrophages,
intrarenal production of inducible nitric oxide synthase,
tumor necrosis factor (TNF)-a, interleukin-12, and CXCL10,
and loss of podocytes. TNF-a was essential for acceleration of
Alport nephropathy, as etanercept (a soluble TNF-a receptor)
entirely abrogated the CpG-DNA effect. Thus, systemic
exposure to CpG-DNA induces classically activated (M1)
macrophages that enhance intrarenal inflammation and
disease progression. Hence, factors that modulate the
phenotype of renal macrophages can affect the progression
of Alport nephropathy and, potentially, other types of
chronic kidney diseases.
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Alport disease results from genetic mutations in genes that
encode for the a3, a4, or a5 chains of type IV collagen
(Col4), which affects the proper assembly of glomerular
basement membranes.1 The abnormal membrane structure
activates adjacent glomerular cells; hence, Alport nephro-
pathy is characterized by an increase in glomerular matrix,
podocyte detachment, and subsequent glomerular scarring.2,3
Similar to most other types of chronic kidney disease, later
stages of Alport nephropathy are associated with major
tubulointerstitial pathology, including mixed interstitial
leukocyte infiltrates and interstitial fibrosis.2,4 In Col4a3-
deficient mice, a genetic model of autosomal recessive Alport
syndrome,5 disease progression is also associated with
leukocytic cell infiltrates in the glomerular and the interstitial
renal compartment.6 In most types of acute and chronic
kidney diseases, leukocyte infiltrates have been shown to
contribute to disease progression by secreting proinflamma-
tory and profibrotic mediators.7–9 This is evidenced by
experimental reduction of renal leukocytes, for example, by
irradiation, targeted deletion, specific toxins, or by chemo-
kine antagonism, which was shown to protect from renal
pathology and to improve renal function.10–13 These data
should also apply to Alport nephropathy, because irradiation
and blockade of chemokine receptor CCR1-mediated renal
macrophage recruitment both proved to reduce renal fibrosis
and prolonged lifespan in Col4a3-deficient mice.14,15 How-
ever, blockade of the proinflammatory CC-chemokine, MCP-
1/CCL2, had no effect on kidney disease and survival of
Col4a3-deficient mice,16 although MCP-1/CCL2 blockade or
MCP-1/CCL2 deficiency prevents macrophage-mediated
renal injury in multiple models of chronic kidney disease.17
We speculated that MCP-1/CCL2 blockade failed to delay
Alport nephropathy because chemokine receptor CCR2þ
macrophages are almost absent in kidneys of Col4a3-deficient
mice.16 In fact, CCR2 is expressed only by classically activated
(M1) macrophages that are readily recruited from the
circulating monocytes into sites of intense inflammation.18,19
However, the extent of tissue inflammation seems to be
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rather low in Alport nephropathy; hence, we speculated that
macrophages in Alport kidneys might display rather nonin-
flammatory phenotypes. Some tumors or, in the late phase of
wound healing, tissue macrophage phenotypes have been
reported to lack CCR2 expression and to display different
functional properties, referred to as the alternatively
activated (M2) macrophages and immunoregulatory macro-
phages.20–23 In fact, the phenotype or activation state of renal
macrophages is thought to significantly affect the extent of
renal inflammation and tissue damage.24 For example, ex vivo
primed M1 or M2 macrophages maintained their phenotype
after adoptive transfer into mice with adriamycin-induced
glomerular sclerosis.25 M1 macrophage infusion aggravated
renal damage and dysfunction, whereas M2 macrophage
infusion reduced renal pathology and improved renal
function. These studies were consistent with our previous
finding that macrophage activation toward the M1 pheno-
type, for example, with Met-RANTES or with bacterial DNA,
aggravates immune complex glomerulonephritis.26,27
Therefore, we hypothesized that the activation state of
renal macrophages would affect disease progression of Alport
nephropathy of Col4a3-deficient mice. We speculated that
classically activated macrophages would increase renal
inflammation and accelerate the progression of Alport
nephropathy. To address this topic, we exposed Col4a3-
deficient mice to a series of injections with lipopolysaccharide
(LPS) or to unmethylated cytosine–guanine (CpG) oligo-
deoxynucleotides. CpG-DNAwas selected because it mimicks
the potential of bacterial DNA to selectively activate
macrophages and dendritic cells through Toll-like receptor
(TLR)9.28 LPS mimicks infection with Gram-negative
bacteria and activates macrophages through TLR4. By using
this study design, we also addressed the question whether
infections affect the progression of Alport nephropathy, for
example, by modulating intrarenal inflammation.
RESULTS
Renal leukocyte subsets in Col4a3-deficient mice
CD45þ leukocytes accumulate in glomeruli and in the
tubulointerstitial compartment during the progression of
Alport nephropathy in Col4a3-deficient mice (Figure 1a).
Hence, we first characterized the intrarenal leukocyte subsets
by flow cytometry. Kidneys of Col4a3-deficient mice
contained increased numbers of CD45þ leukocytes from
6 weeks of age (Figure 1b). Gating CD45þ cells with
additional surface markers allowed us to quantify leukocyte
subsets in renal cell suspensions. F4/80þ /CD11cþ and
F4/80/CD11cþ dendritic cells, as well as F4/80þ /CD11c
macrophages were the largest leukocyte populations in
kidneys of Col4a3-deficient mice (Figure 1b). Almost all the
renal macrophages were negative for Ly6C, a marker
of proinflammatory macrophages (data not shown).
CD3þ /CD4þ and CD4þ /CD8þ T cells and Ly6G-
positive neutrophils were also present in kidneys of Col4a3-
deficient mice at 6 weeks (Figure 1b). Thus, the progression
of Alport nephropathy is associated with infiltrates of
leukocytes, especially of macrophages and dendritic cells,
which do not display markers of classically activated
phenotypes.
Systemic exposure to CpG-DNA shortens the lifespan of
Col4a3-deficient mice
CpG-DNA and LPS are known triggers of leukocyte
activation. CpG-DNA activates murine B cells, macrophages,
and dendritic cells through the endosomal TLR9/MyD88
signaling pathway.29 In contrast, LPS activates leukocytes as
well as nonimmune cells through TLR4 on the cell surface,
which can activate MyD88 as well as TRIF signaling.30
Col4a3-deficient and wild-type mice received seven injections
of CpG-DNA or LPS on alternate days starting from 4 weeks
of age at a dose of 40 or 10 mg, respectively. These doses
were selected because they induced similar plasma levels of
interleukin-6 (IL-6) and MCP-1/CCL2 at 6 h after single
injection into 4-week-old Col4a3-deficient mice (data not
shown). Following up all mice until death revealed that
CpG-DNA significantly reduced the lifespan of Col4a3-
deficient mice, as documented by a mean survival of 46 days
versus 76 days in saline-treated Col4a3-deficient mice
(Figure 2). In contrast, LPS had no effect on the survival of
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Figure 1 | Infiltrating leukocytes in murine Alport
nephropathy. (a) Renal sections were obtained from 6-week-old
wild-type (WT) and Col4a3-deficient mice and stained for CD45 to
identify infiltrating leukocytes. Representative images are shown
and glomeruli are indicated by asterisks and CD45þ cells are
indicated by arrows. Note that CD45þ cells infiltrate glomeruli
and the interstitial compartment of Col4a3-deficient mice. Original
magnification  200. (b) Renal cell suspensions were prepared for
leukocyte flow cytometry from 4- and 6-week-old wild-type and
Col4a3-deficient mice, as described in Materials and Methods.
Data represent the percentage of all kidney cells±s.e.m. from
6 to 7 mice in each group. *Po0.05, **Po0.01, ***Po0.001
wild-type versus 6-week-old Col4a3-deficient mice.
DC, dendritic cells.
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Col4a3-deficient mice. In addition, CpG-DNA and LPS
injections both did not affect the 100% survival in wild-
type mice until 150 days of age. Thus, systemic exposure to
CpG-DNA, but not to an equipotent dose of LPS, shortens
the lifespan of Col4a3-deficient mice.
CpG-DNA, but not LPS, aggravates Alport nephropathy in
Col4a3-deficient mice
Does the effect of CpG-DNA on the lifespan of Col4a3-
deficient mice relate to an acceleration of Alport nephro-
pathy? To answer this question, we treated a second cohort of
mice and performed a cross sectional analysis of all groups at
6 weeks of age. Renal sections from all groups of mice were
stained with Periodic acid-Schiff and the extent of glomer-
ulosclerosis was quantified by a semiquantitative sclerosis
score ranging from 0 to 4, as described in the Materials and
Methods. In Col4a3-deficient mice, CpG-DNA significantly
increased the percentages of glomeruli with a sclerosis score
of 3 or 4 and reduced those with a score of 0 and 1, indicating
a shift toward more severe glomerular lesions (Figure 3a
and c). This was associated with a significant reduction in the
number of podocytes per glomerulus (Figure 3b and d). In
contrast, LPS did not affect the aforementioned glomerular
abnormalities in Col4a3-deficient mice (Figure 3). Neither
CpG-DNA nor LPS injections affected the normal glomerular
structure in wild-type mice (Figure 3a). At the ultrastructural
level, the characteristic abnormalities of Alport nephropathy,
that is, glomerular basement membrane irregularities and
podocyte foot process effacement, became evident in Col4a3-
deficient mice (Figure 4a). Additional extensive accumulation
of extracellular matrix and podocyte damage was seen in
P = 0.006
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Figure 2 | Life span of Col4a3-deficient mice. Wild-type (WT)
and Col4a3-deficient mice were treated with saline,
lipopolysaccharide (LPS), or cytosine–guanine (CpG)-DNA from 4
to 6 weeks of age, as indicated. Survival time is illustrated as
Kaplan–Meier curve.
0
1
2
3
4
†‡†‡
†‡
†‡
G
lo
m
er
u
lo
sc
le
ro
si
s 
(%
)
*
*
*
W
T-
1-
po
sit
ive
 c
e
lls
WT saline
WT saline
Col saline
Col saline
Col CpGCol LPS
Col LPS Col CpG
25
20
15
10
5
0
WT Saline LPS CpG
100
80
60
40
20
0
Col4a3 –/–
Col4a3 –/–
Wild type
Saline LPS CpG Saline LPS CpG
†
Figure 3 |Renal histopathology in 6-week-old wild-type (WT)
and Col4a3-deficient mice. (a) The extent of glomerulosclerosis
was evaluated in mice of all groups by using a semiquantitative
sclerosis score ranging from 0 (no sclerosis) to 4 (global sclerosis),
as described in Materials and Methods. Data represent
means±s.e.m. wPo0.05/zPo0.01 versus saline-treated mice of the
same genotype. (b) The number of glomerular podocytes was
quantified by counting WT-1þ cells in 15 glomeruli per section.
Data represent means±s.e.m., *Po0.05 versus wild type, wPo0.05
versus saline-treated mice of the same genotype. Renal sections
of wild-type and Col4a3-deficient mice were stained with periodic
acid-Schiff solution (c) or anti-WT-1 (d). The figure includes
representative images of single glomeruli from mice of all groups
as indicated; original magnification  400. CpG, cytosine–guanine;
LPS, lipopolysaccharide.
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CpG-DNA-injected Col4a3-deficient mice only (Figure 4b).
In contrast, LPS rather caused activation of glomerular
endothelial cells, as illustrated by luminal tubular extensions
of endothelial cells (Figure 4b). These morphological changes
were associated with an increase of albuminuria and blood
urea nitrogen levels in CpG-DNA-treated Col4a3-deficient
mice (Figure 5). Together, the effect of CpG-DNA on lifespan
is associated with an acceleration of Alport nephropathy.
CpG-DNA increases the numbers of activated renal
macrophages in Col4a3-deficient mice
Among those cells that infiltrate the kidney in Alport
nephropathy, only macrophages and dendritic cells express
TLR9.29 Hence, we speculated that CpG-DNA injections may
aggravate Alport nephropathy by altering numbers of these
cells in kidneys of Col4a3-deficient mice. To address this
issue, we performed quantitative flow cytometry of renal cell
suspensions from mice of all groups at 6 weeks of age. CpG-
DNA significantly increased the amount of renal F4/80þ /
CD11c macrophages (and CD8þ T cells), but not those of
renal CD11cþ dendritic cells in Col4a3-deficient mice
(Figure 6). This was consistent with increased numbers of
interstitial F4/80þ cells as well as Mac2þ glomerular
macrophages in renal sections of Col4a3-deficient mice, as
determined by immunostaining (Figure 7). In contrast, LPS
injections did not affect renal leukocyte numbers in Col4a3-
deficient mice (Figures 6 and 7), and neither CpG-DNA nor
LPS injection affected the numbers of renal leukocytes
in wild-type mice (data not shown). Did CpG-DNA
injections also affect the functional phenotype of intrarenal
macrophages? We addressed this question in various ways.
We used, for example, flow cytometry to quantify the
numbers of Ly6Chi intrarenal macrophages, which represent a
classically activated proinflammatory (M1) phenotype.19,23
CpG-DNA injections significantly increased the numbers
of intrarenal Ly6Chi-positive macrophages, as compared with
LPS- or saline-treated Col4a3-deficient mice (Figure 6b).
In summary, CpG-DNA accelerates kidney disease in
WT saline
WT saline
Col saline
Col saline
Col LPS Col CpG
Figure 4 |Glomerular ultrastructure in 6-week-old Col4a3-
deficient mice. Electron microscopy was applied to assess the
glomerular ultrastructure in 6-weeks-old wild-type (WT) and
Col4a3-deficient mice. (a) Note that lack of Col4a3 is associated
with irregular GBM thickness (c) and podocyte foot process
effacement ( ), as compared with age-matched wild-type mice
(original magnification  25 000). (b) At lower magnification
( 3150), changes in glomerular matrix and capillary structure
between wild-type and Col4a3-deficient mice become visible.
Note that exposure of Col4a3-deficient mice to CpG-DNA caused
extensive accumulation of extracellular matrix (*) with major
capillary and podocyte abnormalities, that is, glomerulosclerosis.
By contrast, LPS exposure rather caused activation of glomerular
endothelial cells, evident by tubular extensions into the capillary
lumen (c). CpG, cytosine–guanine; GBM, glomerular basement
membrane; LPS, lipopolysaccharide.
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Figure 5 |Proteinuria and blood urea nitrogen in wild-type
(WT) and Col4a3-deficient mice. Proteinuria (a) and blood urea
nitrogen (b) were determined from 6-week-old wild-type and
Col4a3-deficient mice of all groups and calculated as described in
Materials and Methods. Data represent means±s.e.m. *Po0.05,
**Po0.01 versus wild-type mice. CpG, cytosine–guanine;
LPS, lipopolysaccharide.
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Col4a3-deficient mice in association with increased numbers
of classically activated renal macrophages.
CpG-DNA and LPS differently modulate the renal mRNA
expression of macrophage markers
As another way to characterize macrophage polarization, we
quantified a number of macrophage activation markers by
real-time PCR using renal RNA extracts from mice of all
treatment groups. In Col4a3-deficient mice, CpG-DNA
injection increased renal mRNA levels of the following M1
(classically activated) macrophage markers: tumor necrosis
factor (TNF-a), iNOS, IL-12, and CXCL10 (Figure 8a). All of
these markers were rather downregulated in LPS-treated
Col4a3-deficient mice. CpG-DNA injections also induced
some of the markers that refer to M2 (alternatively activated)
macrophages, such as arginine-1, TGF-b, and Fizz-1 (Figure 8b).
All aforementioned results were confirmed by real-time PCR
carried out on mRNA isolates from CD11bþ cells that we
isolated using magnetic beads from mice of all groups (see
Supplementary Figure S1 online). The predominant intra-
renal induction of, for example, TNF-a and iNOS mRNA by
CpG-DNA was consistent with an increased glomerular (and
interstitial) staining intensity by anti-iNOS IgG and anti-TNF
IgG on renal sections of CpG-DNA-treated, but not of
saline- or LPS-treated Col4a3-deficient mice (Figure 7).
Interestingly, TNF-a immunostaining was also positive on
glomerular podocytes (Figure 7). Taken together, mRNA
profiling and immunostaining support the fact that CpG-DNA
accelerates kidney disease in Col4a3-deficient mice by
modulating the phenotype of renal macrophages.
The effect of CpG-DNA on Alport nephropathy
is mediated by TNF-a
Because the effects of CpG-DNA on kidney disease in Col4a3-
deficient mice were associated with a marked induction of
TNF-a, we questioned whether this accounts for the
aggravation of Alport nephropathy. Thus, we treated
additional Col4a3-deficient mice with CpG-DNA together
with or without the TNF-a antagonist, etanercept. Etanercept
completely abrogated the effect of CpG-DNA on the
acceleration of glomerulosclerosis, as glomerular sclerosis
scores were similar or even lower as compared with saline-
treated Col4a3-deficient mice (Figure 9a and b). Similarly,
etanercept significantly increased the numbers of WT-1þ
podocytes in glomerular tufts (Figure 9c and d) and
significantly reduced the albumin–creatinine ratio in CpG-
DNA-treated Col4a3-deficient mice (Figure 10a). The pre-
mature mortality of CpG-DNA-treated Col4a3-deficient mice
was also improved from a mean lethality at 46 days to 77 days
by etanercept treatment, which was identical to saline-treated
Col4a3-deficient mice (Figure 10b). Thus, CpG-DNA accel-
erates Alport nephropathy in Col4a3-deficient mice by
activating renal macrophages to secrete TNF-a.
DISCUSSION
Col4a3-deficient mice represent a suitable model to study the
role of environmental factors in Alport syndrome, because
they replicate the genetic and phenotypical characteristics of
the human Alport syndrome.5 Here, we show that exposure
to CpG-DNA, a synthetic mimic of bacterial DNA ligating
TLR9, increased numbers and activation state of intrarenal
macrophages, a phenomenon that was associated with a
robust acceleration of disease progression. These data suggest
first, that the natural course of Alport nephropathy involves a
low degree of intrarenal inflammation associated with rather
alternatively-activated macrophage infiltrates. Second, envir-
onmental stimuli such as microbial DNA can drive disease
progression by enhancing inflammation by modulating
intrarenal macrophage numbers as well as their phenotype.
Third, TNF-a induction is a major element of CpG-DNA-
induced acceleration of Alport nephropathy.
The phenotypical diversity of tissue macrophages has
evolved as a new research field, but classifying macrophage
phenotypes remains a matter of debate.19,20,22 Classically
activated (M1) macrophages were defined as an IL-12, IL-23,
and major histocompatibility complex II-expressing pheno-
type on interferon-g and TNF-a stimulation.18 In contrast,
IL-4, IL-13, or IL-10 stimulation induces alternatively
activated (M2) macrophages that do not produce the
aforementioned proinflammatory mediators but rather
express IL-10, arginase-1, Fizz-1, and the mannose recep-
tor-1.18 Alternatively activated macrophages seem to pre-
dominate the kidneys of Col4a3-deficient mice and may
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Figure 6 |Cytosine–guanine (CpG)-DNA alters renal leukocyte
infiltrate in 6-week-old Col4a3-deficient mice. (a) Renal cell
suspensions were prepared for leukocyte flow cytometry from
6-week-old wild-type (WT) and Col4a3-deficient mice of all groups.
The marker CD11c identified dendritic cells (DCs), macrophages
were F4/80þ /CD11c negative. Data represent the percentage of
all kidney cells±s.e.m. from 5 to 7 mice in each group. *Po0.05,
**Po0.01 CpG-DNA versus saline-treated Col4a3-deficient mice.
(b) The percentage of Ly6Chi cells gated on CD11bþ population
in kidney. *Po0.05 CpG-DNA versus all groups.
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Figure 7 | Immunostaining of renal sections. Renal sections of wild-type (WT) and Col4a3-deficient mice were stained with appropriate
antibodies as indicated. The figure includes representative images of mice from all groups, original magnification  200 or  400.
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contribute to remodeling of the extracellular matrix. For
example, macrophage metalloelastase was shown to con-
tribute to the digestive damage of the glomerular basement
membrane in Col4a3-deficient mice.31 In contrast, we found
only very few CD11bþ /Ly6Chi macrophages in kidneys of
Col4a3-deficient mice at 6 weeks of age. This may explain
why blocking the CC-chemokine, MCP-1/CCL2, does not
modulate murine Alport nephropathy,16 although MCP-1/
CCL2 blockade reduces the progression of most types of
experimental kidney diseases by preventing the recruitment
and activation of CCR2þ M1 macrophages.18,24 Our data
show that systemic exposure to CpG-DNA is more potent
than LPS to modulate intrarenal macrophages toward a
proinflammatory phenotype, as evidenced by increased
numbers of CD11bþ /Ly6Chi macrophages and renal mRNA
expression of M1 macrophage markers in CpG-DNA-treated
Col4a3-deficient mice. These results are consistent with the
effects of CpG-DNA on cultured macrophages23 and the
effects of CpG-DNA injections in murine models of immune
complex glomerulonephritis.27,32 Although such models
involve effects of CpG-DNA on humoral immunity that
compromise conclusions on the role of glomerular macro-
phage phenotypes, a recent study has documented the role of
activated macrophages in focal segmental glomerulosclerosis.
Wang et al.25 observed that injection of ex vivo CpG-DNA-
primed macrophages accelerated adriamycin nephropathy,
while injection of resting macrophages had no effect. Our
data are consistent with these results, although we had
injected CpG-DNA directly into the mice, thereby mimicking
an environmental and systemic trigger of macrophage
activation. Interestingly, CpG-DNA also induced M2 macro-
phage markers such as arginase-1, TGF-b, mannose receptor-1,
Fizz-1, and IL-10. Macrophage diversity is obviously more
complex in tissue environments and is likely to extend
beyond the M1/M2 paradigm.19 Irrespective of such classify-
ing categories, our data show that TNF-a induction is
functionally crucial during CpG-DNA-accelerated Alport
nephropathy. TNF-a release by classically activated macro-
phages accounts for inflammation and tissue damage
in chronic rheumatic diseases, psoriasis, and Crohn’s
disease. Our finding that CpG-DNA increased renal TNF-a
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Figure 8 |Renal mRNA expression of macrophage phenotype
markers in Col4a3-deficient mice. Total kidney mRNA was
prepared from mice of all groups for real-time reverse
transcriptase PCR. Markers of classically activated (M1) (a) or
alternatively activated (M2) (b) macrophages were quantified and
were calculated as ratio per respective 18s rRNA expression. The
graph shows the mRNA levels of lipopolysaccharide (LPS)- (white
bars) or cytosine–guanine (CpG)-DNA-injected mice (black bars)
relative to the levels of saline-treated mice to indicate induction or
suppression of each marker.
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Figure 9 | Effect of tumor necrosis factor-a (TNF-a) blockade
with etanercept on cytosine–guanine (CpG)-DNA-induced
aggravation of Alport nephropathy. (a) The extent of
glomerulosclerosis was evaluated in mice of all groups by using a
semiquantitative sclerosis score ranging from 0 (no sclerosis) to 4
(global sclerosis), as described in Materials and Methods. Data
represent means±s.e.m. wPo0.05 versus saline-treated/zPo0.05
versus CpG-DNA-treated Col4a3-deficient mice. (b) Renal sections
of Col4a3-deficient mice were stained with periodic acid-Schiff
solution. The figure illustrates representative images of single
glomeruli from mice of all groups as indicated; original
magnification  400. (c) The number of glomerular podocytes
was quantified by counting WT-1þ cells in 15 glomeruli per
section. Data represent means±s.e.m., wPo0.05 versus CpG-DNA-
treated Col4a3-deficient mice. (d) Renal sections of Col4a3-
deficient mice were stained with anti-WT-1. The figure illustrates
representative images of single glomeruli from mice of all groups
as indicated; original magnification  400.
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expression and that TNF-a blockade prevents the accelera-
tion of Alport nephropathy is consistent with the protective
effect of TNF-a inhibitors in renal disease models that are
associated with the presence of classically activated macro-
phages.33–36 In addition, macrophage-derived TNF mediates
podocyte activation and dedifferentiation in vitro.37 This
should explain our finding of TNF-a expression in glomeruli
and podocyte loss after CpG-DNA injection and the
protection from CpG-DNA-induced acceleration of glomer-
ulosclerosis after TNF-a blockade. In contrast, LPS can also
trigger macrophage TNF-a release, for example, in the initial
phase of Gram-negative sepsis, but the induction of TLR4
signaling inhibitors account for LPS tolerance after repetitive
LPS exposure.38
In summary, the progression of murine Alport nephrop-
athy is associated with macrophage infiltrates of nonin-
flammatory phenotypes. Exposure to bacterial CpG-DNA
accelerates podocyte loss and glomerulosclerosis in Col4a3-
deficient mice by increasing the numbers of classically
activated macrophages that release proinflammatory media-
tors such as TNF-a. We conclude that environmental stimuli
that modulate renal macrophages toward a proinflammatory
phenotype accelerate the progression of glomerulosclerosis
such as that in Alport nephropathy.
MATERIALS AND METHODS
Animal studies
Col4a3-deficient and wild-type littermate mice in identical SvJ129
genetic backgrounds were selected from the available Alport disease
models because of their consistent phenotype leading to uremic
death at B10 weeks of age.5 All mice were bred under specific-
pathogen-free housing conditions and genotyped as described.39 At
the age of 4 weeks, groups of Col4a3-deficient and wild-type mice
(n¼ 12) started to receive seven intraperitoneal injections on
alternate days of 100ml normal saline (vehicle), 10 mg of ultrapure
LPS (Invivogen, San Diego, CA) in vehicle, or 40 mg endotoxin-free
CpG-phosphothioate oligonucleotide 1668 (50-TCGATGACGTTC
CTGATGCT-30; TIB-Molbiol, Berlin, Germany) in vehicle. The
doses of both TLR agonists were selected because they induced
identical serum levels of IL-6 and MCP-1/CCL2, at 6 h after
intraperitoneal injection in Col4a3-deficient and wild-type mice.
One cohort of mice was bled and killed at 6 weeks of age. Another
cohort was followed until death in order to determine lifespan. An
additional cohort of CpG-DNA-treated Col4a3-deficient mice
(n¼ 6–9) was intraperitoneally injected with either saline or
100 mg etanercept (Wyeth, Taplow, Maidenhead, UK) every other
day from week 4 to 6 to block TNF-a.33,36 All experimental
procedures were performed according to the German animal care
and ethics legislation and were approved by the local government
authorities.
Histopathological evaluation
Parts of the kidneys were fixed in 10% formalin in PBS and
embedded in paraffin. Sections (2 mm) were stained with periodic
acid-Schiff reagent. Glomerular sclerotic lesions were assessed using
a semiquantitative score by a blinded observer as follows: 0¼ no
lesion, 1¼o25% sclerotic, 2¼ 25–49% sclerotic, 3¼ 50–74%
sclerotic, 4¼ 75–100% sclerotic, respectively. A total of 15 glomeruli
were analyzed per section.39 For ultrastructural analysis, kidney
specimens of 6-week-old treated and control mice were dissected
and fixed in 0.1mol/l PBS buffer (pH 7.4) supplemented with 0.4%
paraformaldehyde and 2% glutaraldehyde. Polymerization (using
fresh Epon resin) was carried out at 60 1C for 24 h as described.40
Immunohistochemistry
All immunohistological studies were performed on paraffin-
embedded sections as described.39 The following antibodies were
used as primary antibodies: rat anti-Mac2 (glomerular macro-
phages; Cederlane, Ontario, Canada; 1:50), rat anti-F4/80 (inter-
stitial macrophages; Serotec, Oxford, UK; 1:50), rat anti-CD45
(leukocytes; Dianova, Hamburg, Germany; 1:25), rat anti-Wilms
tumor (WT)-1 (podocytes; Santa Cruz, Santa Cruz, CA; 1:200), goat
anti-mTNF-a (R&D Systems, Minneapolis, MN; 1:800). Glomerular
cell counts evaluated only cells of the tuft from 15 glomeruli, and
interstitial cells were counted in 15 high-power fields (400 ).
Renal function parameters
Urine albumin/creatinine ratios and blood urea nitrogen levels were
determined as previously described.26,41 Blood and urine samples
were collected from each animal at the end of the study. Urine
albumin concentration was measured using a commercial mouse
albumin ELISA quantitation kit (Bethyl Laboratories, Montgomery,
TX) and urinary creatinine concentrations were determined
according to the Jaffe´ method (DiaSys Diagnostic Systems,
Holzheim, Germany). The values of urinary albumin and creatinine
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Figure 10 | Effect of tumor necrosis factor-a (TNF-a) blockade
on proteinuria and lifespan of cytosine–guanine (CpG)-DNA-
accelerated Alport nephropathy. (a) Proteinuria was
determined in 6-week-old wild-type (WT) and Col4a3-deficient
mice, the latter being treated either with CpG-DNA only or CpG-
DNA and etanercept. Data represent means of urinary albumin/
creatinine ratios±s.e.m. (b) CpG-DNA-treated Col4a3-deficient
mice were injected with etanercept from 4 to 6 weeks of age as
indicated. Survival time is illustrated as Kaplan–Meier curve.
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were converted to the same unit and albumin value (mg/dl) was
divided by creatinine value (mg/dl). Blood urea nitrogen in plasma
was measured using a commercially available kit (DiaSys Diagnostic
Systems).
Isolation and flow cytometry of renal leukocytes
Renal cell suspensions were prepared and stained for flow cytometry
using a FACScalibur machine (BD, Heidelberg, Germany) as
previously described.42 In brief, kidneys were mechanically dis-
rupted and incubated in 1 Hanks’ balanced salt solution
containing 1mg/ml collagenase type I and 0.1mg/ml deoxyribonu-
clease type I (Sigma-Aldrich, Steinheim, Germany) for 20min at
37 1C. After washes, tissues were incubated in 5ml of 2mmol/l
EDTA in 1 Hanks’ balanced salt solution (without calcium and
magnesium) for 20min at 37 1C. The supernatant containing
isolated cells was kept on ice, and for a second enzyme step, the
remaining pellet was incubated in 5ml of 1mg/ml collagenase I in
1 Hanks’ balanced salt solution for 20min at 37 1C. The
suspension was subsequently passed through a 19- and 27-gauge
needle, and pooled with the first supernatant from the EDTA
incubation. Cells were filtered through a 70-mm cell strainer (BD)
and washed twice in PBS. All washing steps were performed in FACS
buffer (PBS containing 0.2% of BSA and 0.1% of NaAzide). Renal
leukocytes were characterized by using the following antibodies:
phycoerythrin-conjugated anti-CD45 (clone 30-F11, BD), phycoer-
ythrin- or allophyocyanin-conjugated anti-CD11b (clone M1/70,
BD), FITC-conjugated anti-CD3e (clone 145-2C11, BD), anti-
CD11c (clone N418, Serotec), anti-Ly6G (clone 1A8), anti-Ly6C
(clone AL-21, BD), allophyocyanin-conjugated anti-CD4 (clone
RM4-5, BD), F4/80 (clone CL:A3-1, Serotec), anti-Ly6G and C
(clone RB6-8C5, BD), and PerCp-conjugated anti-CD8a (clone 53-
6.7, BD). For some studies renal CD11bþ macrophages were
isolated from renal cell suspensions by using microbead-conjugated
antibodies (Miltenyi Biotech, Bergisch-Gladbach, Germany).
Real-time quantitative reverse transcriptase PCR
Total RNAwas isolated from kidney or cells using an RNA extraction
kit (QIAGEN, Hilden, Germany) according to the manufacturer’s
instructions, and RNA quality was assessed using agarose gels. After
isolation of RNA, cDNA was generated using reverse transcriptase
(Superscript II; Invitrogen, Carlsbad, CA). SYBR Green dye
detection system was used for quantitative real-time PCR on Light
Cycler 480 (Roche, Mannheim, Germany) using 18s rRNA as a
housekeeper gene. Gene-specific primers (300 nM, Metabion,
Martinsried, Germany) were used as listed in Table 1. Controls
consisting of ddH2O were negative for target and housekeeper genes.
To reduce the risk of false-positive Cp, the high confidence algorithm
was used. The melting curves profiles were analyzed for every sample
to detect eventual unspecific products or primer dimers.
Statistical analysis
Paired Student’s t-test was used for the comparison of single groups.
A value of Po0.05 was considered to indicate statistical significance.
Survival curves were compared by Kaplan–Meier analysis by log-
rank two-tailed testing.
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